Clinical Research Directory
Browse clinical research sites, groups, and studies.
Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations
Sponsor: Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.
Key Details
Gender
FEMALE
Age Range
25 Years - Any
Study Type
OBSERVATIONAL
Enrollment
400
Start Date
2018-01-04
Completion Date
2027-01
Last Updated
2026-02-09
Healthy Volunteers
No
Conditions
Interventions
Salvia sample
salvia sample
Questionnaires
Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
Locations (7)
Dana Farber Cancer Institute (Data Collection Only)
Boston, Massachusetts, United States
Memorial Sloan-Kettering at Basking Ridge
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Commack
Commack, New York, United States
Memorial Sloan Kettering Westchester
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Memorial Sloan Kettering Nassau
Uniondale, New York, United States
Abramson Cancer Center at University of Pennsylvania Medical Center (Data Collection Only)
Philadelphia, Pennsylvania, United States